$4.51
1.35% yesterday
Nasdaq, Nov 17, 10:00 pm CET
ISIN
US00289Y1073
Symbol
ABEO

Abeona Therapeutics, Inc. Stock price

$4.51
-0.87 16.17% 1M
-1.72 27.61% 6M
-1.06 19.03% YTD
-1.35 22.97% 1Y
+0.54 13.60% 3Y
-27.49 85.91% 5Y
-95.74 95.50% 10Y
-4,370.49 99.90% 20Y
Nasdaq, Closing price Mon, Nov 17 2025
+0.06 1.35%
ISIN
US00289Y1073
Symbol
ABEO
Industry

Key metrics

Basic
Market capitalization
$244.4m
Enterprise Value
$57.0m
Net debt
positive
Cash
$207.1m
Shares outstanding
52.4m
Valuation (TTM | estimate)
P/E
3.0 | 3.5
P/S
611.0 | 8.7
EV/Sales
142.6 | 2.0
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
40.4%
Return on Equity
-144.8%
ROCE
-39.8%
ROIC
-468.9%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$400.0k | $28.0m
EBITDA
$-81.7m | -
EBIT
$-83.2m | $-67.8m
Net Income
$82.4m | $68.0m
Free Cash Flow
$-82.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-40.5% | -
EBIT
-37.0% | -5.5%
Net Income
215.9% | 206.7%
Free Cash Flow
-62.8%
Margin (TTM | estimate)
Gross
-122.0%
EBITDA
-20,412.5% | -
EBIT
-20,802.3%
Net
20,587.5% | 242.6%
Free Cash Flow
-20,590.0%
More
EPS
$1.5
FCF per Share
$-1.6
Short interest
21.6%
Employees
136
Rev per Employee
$0.0
Show more

Is Abeona Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,042 stocks worldwide.

Abeona Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Abeona Therapeutics, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Abeona Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.40 0.40
-
100%
- Direct Costs 0.49 0.49
-
123%
-0.49 -0.49
-
-123%
- Selling and Administrative Expenses 54 54
93% 93%
13,483%
- Research and Development Expense 29 29
11% 11%
7,273%
-82 -82
40% 40%
-20,413%
- Depreciation and Amortization 1.56 1.56
40% 40%
390%
EBIT (Operating Income) EBIT -83 -83
37% 37%
-20,802%
Net Profit 82 82
216% 216%
20,588%

In millions USD.

Don't miss a Thing! We will send you all news about Abeona Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Abeona Therapeutics, Inc. Stock News

Positive
Seeking Alpha
6 days ago
Abeona Therapeutics delivered strong 3Q25 results, with a narrowed net loss and $207.5 million in cash supporting a two-year runway. Zevaskyn's commercial launch is delayed to 4Q25 due to FDA assay requirements, but demand and payer coverage remain robust, aided by a new CMS J-code. ABEO's financials improved significantly, with reduced R&D expenses and a strengthened balance sheet, positioning...
Neutral
Seeking Alpha
6 days ago
Abeona Therapeutics Inc. ( ABEO ) Q3 2025 Earnings Call November 12, 2025 8:30 AM EST Company Participants Gregory Gin - Vice President of Investor Relations & Corporate Communications Vishwas Seshadri - President, CEO & Director Brian Kevany - Senior VP, CTO & CSO Madhav Vasanthavada - Senior VP, Chief Commercial Officer & Head of Business Development Joseph Vazzano - Chief Financial Officer C...
Positive
The Motley Fool
6 days ago
Abeona stock surged over 25% after reporting strong earnings and receiving positive updates on Zevaskyn. Major insurers now cover Zevaskyn, and patient identification is progressing.
More Abeona Therapeutics, Inc. News

Company Profile

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Head office United States
CEO Vishwas Seshadri
Employees 136
Founded 1974
Website abeonatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today